Biopas is a leading pharmaceutical company in Latin America, specializing in the in-licensing, marketing, and sale of cutting-edge specialty pharmaceutical products, with annual sales of approx. USD 220 m. The founders of Biopas will become shareholders of Swixx Biopharma. The transaction is expected to close in June or July 2024, subject to regulatory approvals and customary conditions. The Homburger team advising Biopas and its founders comprises Andreas Müller, Anna Peter, Hans Glent Abildgaard and Harun Cetin (all Corporate / M&A), Stefan Bindschedler (Financing and Investment Products) as well as Reto Heuberger and Philippe Weber (both Tax).

---